Navigation Links
Allos Therapeutics Appoints Bruce K. Bennett as Vice President, Manufacturing
Date:1/28/2008

WESTMINSTER, Colo., Jan. 28 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced the appointment of Bruce K. Bennett as Vice President, Manufacturing. In this position, Mr. Bennett will lead the Company's manufacturing functions to support the continued development and potential commercialization of Allos' product candidates.

"We are delighted to welcome Bruce to Allos," said Paul L. Berns, President and CEO. "Bruce's experience in all aspects of pharmaceutical manufacturing and his demonstrated leadership in the pharmaceutical, biotechnology and life sciences industries will be valuable as we look to advance our product candidates in support of our mission of developing and commercializing promising new therapies for cancer patients."

Mr. Bennett has over 25 years of manufacturing experience in the pharmaceutical, medical device and biotechnology industries. Since 2006, Mr. Bennett has served as an independent consultant focused on the development of business operations, technical and supply chain solutions for biotechnology and pharmaceutical companies. From 2002 to 2006, Mr. Bennett served as Vice President, Manufacturing at La Jolla Pharmaceuticals, where he led a 50 member team in manufacturing, materials management, vendor and commercial development, quality control, validation, engineering, facilities, and environmental health and safety. Prior to La Jolla, Mr. Bennett served as Vice President, Operations at Provasis Therapeutics from 2000 to 2002, and as Vice President, Operations, RA/QA/QC and Commercial Development at Via Medical Corporation from 1997 to 2000. From 1987 to 1997, Mr. Bennett served as a senior operations executive of various pharmaceutical, biotechnology and other compan
'/>"/>

SOURCE Allos Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Allos Therapeutics to Present at the 2007 RBC Capital Markets Healthcare Conference
2. Allos Therapeutics Reports Third Quarter 2007 Financial Results
3. Allos Therapeutics to Present at the 2007 Acumen BioFin Rodman & Renshaw Conference
4. Ocera Therapeutics Receives Orphan Drug Status for AST-120 for Pouchitis
5. Transition Therapeutics Announces Appointment of Vice-President of Business Development
6. Cell Therapeutics, Inc. (CTI) Completes Acquisition of Lymphoma Drug Zevalin(R) From Biogen Idec for Sales and Marketing in the United States
7. Transition Therapeutics Announces Milestone Payment from Elan
8. ImaRx Therapeutics Submits Urokinase Data to FDA Supporting Extended Expiration Dating
9. Reckitt Benckiser Commences Cash Tender Offer for All Outstanding Shares of Adams Respiratory Therapeutics
10. Nektar Announces Agreement With Baxter to Develop New PEGylated Therapeutics for Hemophilia
11. Dr. Peter B. Corr Joins Team at Celtic Therapeutics as General Partner
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2014)... better understanding of drug interactions, which are a major ... two or more medications are taken at the same ... the other. Similarly, one drug may magnify the ... major cause of illness and hospitalization. However, there ... drug studies in humans. Limits come in part ...
(Date:4/24/2014)... coated with an antimicrobial peptide could help to lower the ... Optometry and Vision Science , official journal of ... is published by Lippincott Williams & Wilkins , a ... animals and now humans support the biocompatibility and safety of ... new research by Debarun Dutta, B.Optom, of The University of ...
(Date:4/24/2014)... will bring together national experts to discuss solutions ... inaugural Brain Health Summit, titled "The Human Brain: ... Dr. Sandra Bond Chapman, founder and chief director ... Grassley (R-IA), U.S. Representative Chaka Fattah (D-PA) and ... Early Learning, U.S. Department of Education. The day ...
(Date:4/24/2014)... End-of-life aspects, the corresponding terminology, and the relevance ... considered in publications on randomized controlled trials (RCTs). ... the German Institute for Quality and Efficiency in ... as final report. , Together with external experts, ... examples: glioblastoma, lung cancer, malignant melanoma, and pancreatic ...
(Date:4/24/2014)... Ill. It is better to give than to receive ... giving, a new study suggests. , The study found that ... as giving their money to family members, are less likely ... from taking risks or keeping the money for themselves. , ... the National Academy of Sciences . , The study focused ...
Breaking Medicine News(10 mins):Health News:Large-scale identification and analysis of suppressive drug interactions 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 3Health News:Inaugural Brain Health Summit focuses on brain resilience and regeneration 2Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3Health News:Study: Altruistic adolescents less likely to become depressed 2
... & Experimental Allergy reveals that there is no association between ... confidence in being able to provide a safe meal to a ... and as much as 8% of children in the UK alone. ... serious being anaphylaxis, which can cause death. Led by Professor Helen ...
... care improves medical outcomes, investigators from the Regenstrief ... providing a call to action for the training ... well as the burgeoning scientific knowledge needed to ... the Patient-Centered Divide: Transforming Health Care Quality Through ...
... Material (SRM) from the National Institute of Standards ... accurately diagnose Huntington,s disease, an inherited degenerative brain ... 50 and progressively leads to physical impairment, dementia ... developed Huntington,s disease has a 50-50 chance of ...
... in French and Spanish . , ... professors Antonio Campos and Miguel Alaminos (histologists), Mara del Mar ... and the ophthalmologist Miguel Gonzlez Andrades, University Hospital San Cecilio, ... Researchers extracted pig corneal cells and replaced them with human ...
... available in French . Montreal, April 13, ... in Tourette syndrome may be as effective as and even ... study published in a special edition of the International Journal ... of the Louis-H. Lafontaine Hospital affiliated with Universit de Montral, ...
... For the first time, scientists at Toronto General Hospital, ... that the Toronto XVIVO System can safely and effectively ... lungs so that they can be successfully transplanted into ... the donor organ pool and improve outcomes after transplantation. ...
Cached Medicine News:Health News:Training future doctors to enlist patients as partners in care 2Health News:New NIST SRM helps improve diagnosis of Huntington's disease 2Health News:Tourette Syndrome: non-drug therapy to reduce tics 2Health News:Toronto XVIV0 Lung Perfusion System allows high-risk lungs to be safely transplanted 2Health News:Toronto XVIV0 Lung Perfusion System allows high-risk lungs to be safely transplanted 3Health News:Toronto XVIV0 Lung Perfusion System allows high-risk lungs to be safely transplanted 4
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly ... and painless for patients to self-inject prescription drugs in the ... including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... grow to $220B by 2018, according to analysts.   Many of ...
(Date:1/14/2014)... HARRISBURG, Pa. , Jan. 14, 2014 Dynamic Healthcare ... ("GMH"), announced today that it acquired Progressive Home Medical Equipment, ... January 7, 2014. The terms of the acquisition were not ... medical equipment ("DME") company providing a wide range of sleep, ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... Pharmaceuticals, Inc. (Nasdaq: REGN ) will webcast ... Conference on Wednesday, November 10, 2010.  The presentation is ... Time).  The session may be accessed through the Company,s ... page.  An archived version of the presentation will be ...
... than half of the life sciences start-up companies in ... of funding through the Therapeutic Discovery Project Credit under ... of 2010. Seed ... SonarMed all learned today from the Internal Revenue Service ...
Cached Medicine Technology:Indiana Life Sciences Start Ups Garner More than $1.5 Million in Competitive Federal Funding 2
... SAFE-T-FILL Capillary Blood Collection Tubes are 100% ... a wide range of applications, the Capillary ... tube, attached cap and a micro tube.,The ... the blood into the micro tube thereby ...
... Capillary Blood Collection Tubes are 100% plastic ... wide range of applications, the Capillary Collection ... attached cap and a micro tube.,The capillary ... blood into the micro tube thereby eliminating ...
... Scientifics SAFE-T-FILL Capillary Blood Collection Tubes are ... for a wide range of applications, the ... capillary tube, attached cap and a micro ... draw the blood into the micro tube ...
... Scientifics SAFE-T-FILL Capillary Blood Collection Tubes are ... for a wide range of applications, the ... capillary tube, attached cap and a micro ... draw the blood into the micro tube ...
Medicine Products: